Literature DB >> 24153350

Absence of somatic MYD88 L265P mutations in patients with primary Sjogren's syndrome.

M Voulgarelis1, C P Mavragani2, L Xu3, S P Treon3, H M Moutsopoulos1.   

Abstract

Sjogren's syndrome (SS) is a chronic autoimmune disorder with the highest risk for lymphoma development among all autoimmune diseases. In order to evaluate whether the presence of the recently described MYD88 L265P mutation in patients with Waldenström's macroglobulinemia (WM) is contributory to SS-associated lymphomagenesis, a quantitative allele-specific PCR method was performed in peripheral blood derived from 90 SS patients as well as in minor salivary gland tissues derived from 12 primary SS patients with or without lymphoma. MYD88 L265P was not detected in either of the samples tested. Although the absence of the MyD88 L265P somatic mutation in our SS cohort does not exclude a common germline susceptibility gene in SS, it might suggest a distinct operating pathogenetic mechanism in SS-related lymphoma compared with WM and other hematological malignancies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24153350     DOI: 10.1038/gene.2013.54

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  16 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

3.  BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands.

Authors:  Luca Quartuccio; Sara Salvin; Martina Fabris; Marta Maset; Elena Pontarini; Miriam Isola; Salvatore De Vita
Journal:  Rheumatology (Oxford)       Date:  2012-08-09       Impact factor: 7.580

Review 4.  Activation of the type I interferon pathway in primary Sjogren's syndrome.

Authors:  Clio P Mavragani; Mary K Crow
Journal:  J Autoimmun       Date:  2010-07-31       Impact factor: 7.094

5.  Salivary gland expression level of IκBα regulatory protein in Sjögren's syndrome.

Authors:  Margherita Sisto; Sabrina Lisi; Dario Domenico Lofrumento; Giuseppe Ingravallo; Raffaella De Lucro; Massimo D'Amore
Journal:  J Mol Histol       Date:  2013-02-03       Impact factor: 2.611

6.  Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome.

Authors:  Michael Voulgarelis; Panayiotis D Ziakas; Aristea Papageorgiou; Evangelia Baimpa; Athanasios G Tzioufas; Haralampos M Moutsopoulos
Journal:  Medicine (Baltimore)       Date:  2012-01       Impact factor: 1.889

Review 7.  Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients.

Authors:  Michael Voulgarelis; Fotini N Skopouli
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

8.  MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

Authors:  Lian Xu; Zachary R Hunter; Guang Yang; Yangsheng Zhou; Yang Cao; Xia Liu; Enrica Morra; Alessandra Trojani; Antonino Greco; Luca Arcaini; Marzia Varettoni; Maria Varettoni; Jennifer R Brown; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi; Christopher J Patterson; Robert J Manning; Christina K Tripsas; Neal I Lindeman; Steven P Treon
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

9.  B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome.

Authors:  Adrianos Nezos; Aristea Papageorgiou; George Fragoulis; Dimitrios Ioakeimidis; Michael Koutsilieris; Athanasios G Tzioufas; Haralampos M Moutsopoulos; Michael Voulgarelis; Clio P Mavragani
Journal:  J Autoimmun       Date:  2013-07-09       Impact factor: 7.094

10.  Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development.

Authors:  M N Manoussakis; S Boiu; P Korkolopoulou; E K Kapsogeorgou; N Kavantzas; P Ziakas; E Patsouris; H M Moutsopoulos
Journal:  Arthritis Rheum       Date:  2007-12
View more
  2 in total

Review 1.  Pathogenetic Mechanisms Implicated in Sjögren's Syndrome Lymphomagenesis: A Review of the Literature.

Authors:  Ioanna E Stergiou; Aikaterini Poulaki; Michael Voulgarelis
Journal:  J Clin Med       Date:  2020-11-24       Impact factor: 4.241

Review 2.  Contribution of Genetic Factors to Sjögren's Syndrome and Sjögren's Syndrome Related Lymphomagenesis.

Authors:  Adrianos Nezos; Clio P Mavragani
Journal:  J Immunol Res       Date:  2015-10-15       Impact factor: 4.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.